6 citations
,
July 2011 in “British Journal of Dermatology” A man with KID syndrome developed a rare cancer in a long-term skin infection.
February 2006 in “Inpharma Weekly”
21 citations
,
February 2009 in “Journal of the American Academy of Dermatology” Some cases of tinea capitis, a fungal scalp infection, can look like scarring hair loss due to the body's immune response and the fungus itself.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
February 2023 in “Reactions Weekly”
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Trichophyton mentagrophytes genotype VII is a sexually transmitted fungus causing skin issues, mainly among men who have sex with men in Europe, and requires quick treatment.
STS01 1% effectively promotes hair regrowth with minimal side effects.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
May 2022 in “Reactions Weekly”
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
November 2023 in “Cermin Dunia Kedokteran” Tinea capitis can affect mental health, but treatment improves both health and well-being.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
4 citations
,
January 1989
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
January 2021 in “Our Dermatology Online” Oral tofacitinib successfully treated total body hair loss in one patient.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
May 2022 in “International journal of infectious diseases” A woman with a rare scalp infection was cured after one month of medication.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
22 citations
,
January 2009 in “Medical mycology” A family got a fungal infection from a boy who had contact with rabbits, but they all recovered with treatment.
8 citations
,
May 1989 in “Annals of Saudi Medicine” Tinea capitis is common in the Eastern Province of Saudi Arabia and can be effectively treated.
8 citations
,
April 2006 in “Acta dermato-venereologica” Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
January 2007 in “Journal of the American Academy of Dermatology” Tinea can cause scarring alopecia in children, and fungal culture is crucial for diagnosis.
December 2019 in “International Journal of Research in Dermatology” Strong steroid cream works better than tretinoin cream for patchy scalp hair loss.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.